Pediatric Brain Tumor Consortium   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Memphis TN United States (1999)

Organization Overview

First Clinical Trial
2000
NCT00006247
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Pediatric Brain Tumor Consortium

Active Ingredients

Drugs in Phase 2 Trials (30)

131 i-omburtamab (1 trial)

acetaminophen (tylenol) (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

bevacizumab (avastin) (2 trials)

busulfan (myleran) (2 trials)

capecitabine (xeloda) (2 trials)

cintredekin besudotox (1 trial)

cyclophosphamide (cytoxan) (3 trials)

dabrafenib (tafinlar) (1 trial)

dexamethasone (1 trial)

filgrastim (neupogen) (1 trial)

fludarabine (fludara) (1 trial)

fludeoxyglucose f-18 (1 trial)

gefitinib (iressa) (1 trial)

grn163l (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

irinotecan (Camptosar) (2 trials)

lapatinib (tykerb) (1 trial)

liothyronine (cytomel) (1 trial)

oxaliplatin (eloxatin) (1 trial)

potassium iodide (thyro-block) (1 trial)

selumetinib (1 trial)

silmitasertib (1 trial)

temozolomide (temodar) (4 trials)

tgfa-pe38 immunotoxin (1 trial)

trametinib (mekinist) (1 trial)

veliparib (2 trials)

vismodegib (erivedge) (3 trials)

zarnestra (1 trial)

Drugs in Phase 1 Trials (29)

apx005m (1 trial)

azurin-derived cell-penetrating peptide p28 (1 trial)

carmustine (bicnu) (1 trial)

cediranib (1 trial)

cilengitide (1 trial)

enzastaurin (1 trial)

everolimus (zortress) (1 trial)

her2 car-t cell (1 trial)

hsv-1716 (1 trial)

incb7839 (1 trial)

karenitecin (1 trial)

lenalidomide (revlimid) (1 trial)

mk-0752 (1 trial)

o6-benzylguanine (2 trials)

onrigin (1 trial)

palbociclib (ibrance) (1 trial)

panobinostat (farydak) (1 trial)

pembrolizumab (keytruda) (1 trial)

polifeprosan (1 trial)

pomalidomide (pomalyst) (1 trial)

ptc299 (1 trial)

ribociclib (kisqali) (1 trial)

romiplostim (nplate) (1 trial)

sargramostim (leukine) (1 trial)

savolitinib (1 trial)

sch66336 (1 trial)

survaxm (1 trial)

topotecan (hycamtin) (1 trial)

urea (1 trial)

Drugs in Other Trials (8)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

etoposide (vepesid) (1 trial)

isotretinoin (accutane) (1 trial)

peripheral blood hematopoietic cell (1 trial)

thiotepa (1 trial)

vincristine (oncovin) (1 trial)

vorinostat (zolinza) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adamantinoma (Phase 2)

Anemia (Phase 2)

Astrocytoma (Phase 2)

Brain Neoplasms (Phase 1)

Brain Stem Neoplasms (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Choroid Plexus Neoplasms (Phase 1)

Colorectal Neoplasms, Hereditary Nonpolyposis (Phase 1)

Craniopharyngioma (Phase 2)

Ependymoma (Phase 2)

Fanconi Anemia (Phase 2)

Fanconi Syndrome (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Gliosarcoma (Phase 2)

Leukemia (Phase 1)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 1)

Medulloblastoma (Phase 2)

Meningeal Carcinomatosis (Phase 1)

Meningioma (Phase 1)

Meningitis (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Germ Cell and Embryonal (Phase 1)

Neoplasms, Neuroepithelial (Phase 2)

Nervous System Neoplasms (Phase 2)

Neuroblastoma (Phase 1)

Neuroectodermal Tumors (Phase 2)

Neuroectodermal Tumors, Primitive (Phase 2)

Neurofibroma (Phase 2)

Neurofibromatoses (Phase 2)

Neurofibromatosis 1 (Phase 2)

Oligodendroglioma (Phase 2)

Optic Nerve Glioma (Phase 2)

Pinealoma (Phase 1)

Retinoblastoma (Phase 1)

Rhabdoid Tumor (Phase 2)

Spinal Cord Neoplasms (Phase 2)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 48
  • # of Trial APIs: 67